Tideglusib clinical trial CrossRefPubMed 8. Lordick F, Lorenzen S, Stollfuss
J, Vehling-Kaiser U, Kullmann F, Hentrich M, Zumschlinge R, Dietzfelbinger H, Thoedtmann J, Hennig M, Seroneit T, Bredenkamp R, Duyster J, Peschel C: Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer 2005, 93: 190–194.CrossRefPubMed 9. Park YH, Kim BS, Ryoo BY, Yang SH: A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br J Cancer 2006, 94: 959–963.CrossRefPubMed 10. Thuss-Patience PC, Kretzschmar A, Reichardt P: Docetaxel in the treatment of gastric cancer. Future Oncol 2006, 2: 603–620.CrossRefPubMed 11. Di Lauro L, Belli F, Arena MG, Carpano S, Paoletti G, Giannarelli D, Lopez M: Epirubicin,
cisplatin and docetaxel combination therapy for metastatic gastric cancer. Ann find more Oncol 2005, 16: 1498–1502.CrossRefPubMed 12. Therasse P, Arbuck SG, Eisenhauer E, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000, 92: 205–216.CrossRefPubMed 13. Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathè G: Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian Selleckchem EPZ5676 rhythm-modulated rate compared with enough constant rate. J Natl Cancer Inst 1990, 82: 1046–1050.CrossRefPubMed 14. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10: 1–10.CrossRefPubMed 15. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358: 36–46.CrossRefPubMed 16. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth
A, Jäger E: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008, 26: 1435–1442.CrossRefPubMed 17. Pozzo C, Barone C: Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents? Oncologist 2008, 13: 794–806.CrossRefPubMed Competing interests The authors declare that they have no competing interests. Authors’ contributions LDL conceived and designed the study, LG, MGA, DS, SIF collected and assembled the data, DG performed the statistical analysis, LDL and ML wrote the manuscript. All authors read and approved the final manuscript.”
“Background Pain is a common problem in cancer patient.